2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

621. Lymphomas: Translational: Molecular and Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1734 EZH2 and CD58 co-define an exhausted high-risk subtype of diffuse large B-cell lymphoma

XiaoTong Wang, MD, Huilai Zhang, PhD2
1 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
2 Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Background
Mutations in EZH2 are frequently observed in diffuse large B-cell lymphoma (DLBCL), yet their prognostic significance and impact on the tumor immune microenvironment remain incompletely defined. CD58, a key co-stimulatory molecule on tumor cells, plays a critical role in T-cell activation, and its loss has been implicated in immune evasion. However, whether EZH2 mutation status, in concert with CD58 alterations, defines distinct DLBCL subgroups with differential clinical outcomes and immune profiles remains unknown. In this study, we aimed to characterize the mutual exclusivity between EZH2 and CD58 mutations, identify a high-risk molecular subtype, and elucidate the epigenetic mechanism through which EZH2 silences CD58 transcription via H3K27me3 modification, with further evaluation of its prognostic and immunomodulatory implications.

Methods
A total of 503 DLBCL patients underwent targeted sequencing, and genomic and transcriptomic data from 3,700 patients across multiple independent cohorts were systematically analyzed. Tumor microenvironment composition was evaluated using ESTIMATE, CIBERSORT, and single-cell RNA-sequencing of 14 treatment DLBCL samples. Survival analysis, co-mutation profiling, and pathway enrichment analysis were performed to assess prognostic stratification and biological correlates. To dissect the epigenetic regulatory mechanism, ChIP-seq was employed to detect EZH2 and H3K27me3 enrichment at the CD58 promoter. Pseudotime trajectory analysis and cell-cell communication inference were applied to single-cell data to trace dynamic expression changes and intercellular interactions. Mechanistic insights were derived from pseudotime trajectory analysis, cell-cell communication inference, and in vitro validation approaches in DLBCL cell lines.

Results
EZH2 mutations were identified in 7% of DLBCL patients and exhibited significant mutual exclusivity with CD58 mutations. The EZH2WT&CD58MUT subgroup defined a high-risk phenotype characterized by a “high infiltration, T-cell high exhaustion” immune profile, accompanied by significant upregulation of PD-L1, TIM3, LAG3, and IDO1. Multi-cohort and single-cell analyses consistently demonstrated a significant inverse correlation between EZH2 and CD58 expression. Multi-cohort and single-cell analyses consistently demonstrated a significant inverse correlation between EZH2 and CD58 expression. CD58-low B cells displayed elevated H3K27me3, malignancy, and immunosuppression scores, while pseudotime trajectory analysis revealed opposing expression dynamics of EZH2 and CD58 during tumor progression. ChIP-seq evidence that EZH2 and its catalytic product H3K27me3 are specifically enriched at the CD58 promoter region. Pharmacological inhibition with SHR2554 restored CD58 expression in a dose-dependent manner, supporting a functional role for EZH2 in CD58 repression.

Conclusion
EZH2 epigenetically silences CD58 transcription via H3K27me3 modification. The mutually exclusive EZH2-CD58 mutational signature enables precise risk stratification of DLBCL. The exhausted EZH2WT&CD58MUT high-risk subgroup may benefit from EZH2 inhibition and immune checkpoint blockade, offering a novel biomarker and combinatorial treatment for DLBCL precision immunotherapy.

XiaoTong Wang, MD: No relevant conflicts of interest to declare.